Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: '17 aag hydrochloride'

Search results for: '17 aag hydrochloride'

Items 21-30 of 42

Page
per page
  1. WEHI-539 hydrochloride
    A8634 WEHI-539 hydrochloride
     1 Citation
    Summary: Bcl-xL inhibitor,high affinity and selective
      ≥28.55 mg/mL
  2. THZ1 Hydrochloride
    B4736 THZ1 Hydrochloride
    Target: Cyclin-Dependent Kinases
    Summary: CDK7 inhibitor
      ≥30.13 mg/mL
  3. TC-A 2317 hydrochloride
    A4489 TC-A 2317 hydrochloride
    Target: Aurora Kinases
    Summary: Aurora kinase A inhibitor,potent and selective
      <39.29 mg/mL
  4. Tubastatin A HCl
    A8547 Tubastatin A HCl
     1 Citation
    Target: Histone Deacetylases (HDACs)
    Summary: HDAC6 inhibitor,potent and selective
      insoluble in EtOH; ≥12.34 mg/mL
  5. SRT1720 HCl
    A4180 SRT1720 HCl
     3 Citation
    Target: Sir2-like Family Deacetylases (Sirtuins)
    Summary: SIRT1 activator
      ≥25.3 mg/mL
  6. Nintedanib (BIBF 1120)
    A8252 Nintedanib (BIBF 1120)
     3 Citation
    Target: VEGFR|PDGFR|FGFR
    Summary: VEGFR/PDGFR/FGFR inhibitor
      insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
  7. Lamivudine
    A8458 Lamivudine
    Target: HBV Proteases
    Summary: Nucleoside analog reverse transcriptase inhibitor
      ≥10.5 mg/mL
  8. SC-514
    B1585 SC-514
    Summary: ATP-competitive IKK-2 inhibitor, orally active
      insoluble in EtOH; insoluble in H2O; ≥50.4 mg/mL
  9. I-BET-762
    B1498 I-BET-762
     4 Citation
    Target: Bromodomains
    Summary: BET inhibitor,highly potent
      ≥21.19 mg/mL
  10. LGX818
    B1174 LGX818
    Target: Raf
    Summary: RAF inhibitor,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥13.38 mg/mL

Items 21-30 of 42

Page
per page
Shop By
Now Shopping by
  1. Specificity Selective Remove This Item
  2. Reported Experiments Cell Experiments Remove This Item
Clear All
Shopping Options
Category
  1. Signaling Pathways 41item
  2. Lab Reagents 1 item
Reversibility
  1. Reversible 3item
  2. Irreversible 1 item
Target
  1. Cyclin-Dependent Kinases 1 item
  2. Proteasome 1 item
  3. Histone Deacetylases (HDACs) 1 item
  4. Raf 1 item
  5. Aurora Kinases 1 item
  6. EZH2 1 item
  7. Bromodomains 1 item
  8. Thymidine Phosphorylases 1 item
  9. VEGFR 1 item
  10. PDGFR 1 item
  11. Phosphodiesterases (PDEs) 1 item
  12. MEK 1 item
  13. FGFR 1 item
  14. Pim 1 item
  15. Sir2-like Family Deacetylases (Sirtuins) 1 item
  16. Deubiquitinating enzymes (DUBs) 1 item
  17. EGFR 1 item
  18. FAK 1 item
  19. Syk 1 item
  20. HSP90 1 item
  21. AMPK 1 item
  22. PKC 1 item
  23. Ca2 /calmodulin-dependent protein kinases (CaMKs) 2item
  24. Pyk2 1 item
  25. 5-HT2 Receptors 2item
  26. S1P receptors 1 item
  27. Myosin light chain kinases (MLCKs) 1 item
  28. 5-HT3 Receptors 1 item
  29. Squalene epoxidases 1 item
  30. Nampt 1 item
  31. Glutamate (Metabotropic) Group I Receptors 1 item
  32. AChE 1 item
  33. HBV Proteases 1 item
  34. IKK 1 item
  35. Calcium-Sensing Receptors (CaSRs) 1 item
  36. CRF1 Receptors 1 item
Related Disease
  1. Acute Myeloid Leukemia 2item
  2. Bacterial Infectios 1 item
  3. Bladder Cancer 2item
  4. Breast Cancer 5item
  5. Cancer 17item
  6. Cervical Cancer 1 item
  7. Chronic Lymphocytic Leukemia 1 item
  8. Colon Cancer 2item
  9. Colorectal Cancer 4item
  10. Erectile Dysfunction 1 item
  11. Glioblastoma 2item
  12. Glioma 2item
  13. Hepatocellular Carcinoma 1 item
  14. HIV Infections 2item
  15. Inflammatory Diseases 2item
  16. Leukemia 1 item
  17. Lung Cancer 3item
  18. Lymphoma 1 item
  19. Melanoma 2item
  20. Multidrug Resistance Studies 1 item
  21. Multiple Myeloma 4item
  22. Narcolepsy 1 item
  23. Non-small Cell Lung Cancer 2item
  24. Ovarian Cancer 1 item
  25. Pancreatic Cancer 3item
  26. Prostate Cancer 4item
  27. Schizophrenia 1 item
  28. Type 2 Diabetes 1 item